One-and-Done: Groundbreaking CRISPR Therapy slashes Cholesterol and Triglycerides in First Human Trial

NEW ORLEANS — In a milestone medical development presented at the American Heart Association’s Scientific Sessions 2025, researchers announced that a single intravenous infusion of an experimental CRISPR-Cas9 gene-editing therapy successfully and safely cut low-density lipoprotein (LDL) cholesterol by nearly 50% and triglycerides by roughly 55%. The Phase 1 clinical trial targets individuals with severe, difficult-to-treat lipid disorders. Simultaneously published in The New England Journal of Medicine, these findings mark the first time gene editing has been successfully applied to a common, chronic condition like cardiovascular disease, rather than ultra-rare genetic disorders, opening the door to a potential “one-and-done” lifetime cure for the world’s leading killer.

Turning Off the Source: How CTX310 Works

The experimental therapy, dubbed CTX310, utilizes lipid nanoparticles—tiny fat bubbles similar to those used in mRNA COVID-19 vaccines—to deliver a molecular CRISPR-Cas9 editing tool directly to the liver. Once inside the liver cells, the tool permanently deactivates the ANGPTL3 (angiopoietin-like protein 3) gene.

The ANGPTL3 gene acts as a biological brake on the body’s natural ability to clear lipids from the bloodstream. By permanently “switching off” this gene, the liver is essentially reprogrammed to continuously clear dangerous fats from circulation.

“This is really unprecedented. A single treatment that simultaneously lowered LDL cholesterol and triglycerides,” said Dr. Luke J. Laffin, M.D., lead author of the study and a preventive cardiologist at the Cleveland Clinic. “If confirmed in larger trials, this one-and-done approach could transform care for people with lifelong lipid disorders and dramatically reduce cardiovascular risk.”

Key Findings at Highest Administered Dose:

Historically, researchers expected a 30% to 40% reduction in lipids to signify a wildly successful trial. The actual results significantly exceeded those projections. Crucially, cholesterol and triglyceride levels began dropping within two weeks of the infusion and remained stably suppressed at the 60-day mark, which was the latest data available for this specific analysis.

The Shift From Daily Pills to Permanent Fixes

For decades, the cornerstone of cardiovascular prevention has relied on daily oral medications, like statins, or bi-weekly injections. However, real-world execution is notoriously flawed.

“Adherence to cholesterol-lowering therapy is one of the biggest challenges in preventing heart disease,” explained study co-author Dr. Steven E. Nissen, M.D., FAHA, and chief academic officer at the Cleveland Clinic Heart, Vascular and Thoracic Institute. “Many patients stop taking their cholesterol medications within the first year. The possibility of a one-time treatment with lasting effects could be a major clinical advance.”

The biological rationale behind disabling ANGPTL3 is rooted in natural human genetics. Scientists have long observed individuals born with rare, natural “loss-of-function” mutations in their ANGPTL3 gene. These individuals live their entire lives with remarkably low cholesterol and triglyceride levels without presenting any negative side effects. Most importantly, they possess an exceptionally low lifetime risk of atherosclerotic cardiovascular disease. CTX310 mimics this protective genetic anomaly. As Dr. Laffin noted, “People want a fix, not a bandage.”

Safety Profile and Initial Study Limitations

As with any first-in-human medical trial, safety remains the paramount metric. CTX310 demonstrated a highly favorable short-term safety profile. A few participants experienced minor, transient infusion-related reactions, including back pain and nausea, which quickly resolved with standard medication. One participant exhibited a brief spike in liver enzymes, which returned to normal within days without medical intervention.

While one participant in the lowest dosage group passed away suddenly 179 days post-treatment, independent monitors determined the death was completely unrelated to the gene-editing therapy.

Despite these promising signs, independent experts urge cautious optimism. Because it is a Phase 1 trial, the limitations are inherent and significant:

• Small Sample Size: The trial evaluated only 15 participants.

• Lack of Diversity: The participant pool was heavily skewed, with 87% being male (13 of 15) and 93% identifying as White (14 of 15).

• Short Follow-up: This initial analysis reported on just 60 days of post-treatment data.

• Geographic Scope: Testing was limited to six clinical sites across Australia, New Zealand, and the United Kingdom.

“These findings support a potential role for gene editing with regard to lipid management if subsequent studies establish safety and efficacy,” the research team explicitly concluded, highlighting the preliminary nature of the data.

The Public Health Scale

The global implications of a permanent cardiovascular cure cannot be overstated. According to the American Heart Association’s 2025 Heart Disease and Stroke Statistics, cardiovascular disease accounts for roughly 32% of all global deaths annually. In the United States alone, an estimated 86.4 million adults—approximately 35% of the population—live with elevated total cholesterol levels of 200 mg/dL or higher.

Global Deaths Caused by Cardiovascular Disease Annually: ~32%
U.S. Adults Living with Elevated Cholesterol (≥200 mg/dL): ~35% (86.4 Million)

Transitioning CRISPR therapies from niche, rare diseases into the public health mainstream requires cleared hurdles regarding long-term safety. Because gene editing makes irreversible changes to human DNA, the U.S. Food and Drug Administration (FDA) recommends tracking all treated patients for up to 15 years to monitor for “off-target” genetic mutations or long-term liver toxicities.

What This Means for Patients Today

For individuals currently managing high cholesterol or coping with familial lipid conditions, this news offers an exciting glimpse into the future of medicine, but it does not change current care plans.

1. The Therapy is Investigational: CTX310 is not approved by regulatory bodies and is not commercially available.

2. Do Not Stop Current Medications: Standard therapies like statins remain the proven, frontline defense against heart attacks and strokes. Patients must not alter or discontinue their prescriptions without explicit consulting from their physician.

3. Expanded Trials are Coming: Phase 2 trials, designed to evaluate the treatment in much larger and far more diverse patient populations, are scheduled to commence in late 2025 and early 2026.

Future Hurdles: Cost and Logistics

Even if future trials prove highly successful, widespread distribution faces societal roadblocks. Gene-editing treatments are historically among the most expensive therapies in the world. Additionally, as noted in the 2026 ACC Scientific Statement on Gene Editing Therapy, clinical translation will rely heavily on creating efficient, non-toxic delivery vectors and ensuring the human immune system doesn’t reject the editing enzymes.

Nevertheless, biotech confidence is booming. Approximately a dozen pharmaceutical firms are now developing gene-editing pipelines targeting high cholesterol. CRISPR Therapeutics, the developer behind CTX310, is already expanding its scope to engineer similar “one-and-done” gene-editing avenues for high blood pressure and transthyretin amyloidosis.

“This treatment is still very early in development, but if future trials continue to demonstrate safety and efficacy, the therapy has the potential to change the way we treat lipid disorders,” says Dr. Laffin. The path toward a vaccine-like solution for heart disease has officially begun.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.medscape.com/viewarticle/could-gene-editing-eventually-offer-one-time-treatment-cvd-2026a1000gsz